Chemo regimen called 'new standard' in advanced PCa

Studies show improved survival, longer time to progression with docetaxel-based therapy

Related Content:

Drug Therapy

Pivotal data for lumasiran in PH1 published in NEJM

Nedosiran explored in primary hyperoxaluria type 3

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria